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insenion oi a copper coil or thrombin to induce tluombus 
formation. The arferid thrombus in human atherosclerotic 
arteries is almost always a platetet-initiated event (7) in 
which fibrin and circulating cells become secondarily incor- 
porated. The arterial Ihrombus in animals may be platelet- 
rich or consist mostly of red blaod cells (9). Furthermore. 
there are numerous variations in platelet responses to ago- 
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The present study. In this issue of the Journal, Mickclson 
et al. (1) show that only high doses of aspirin given inrravc- 
nously are effective in protecting against formation of elec- 
trically induced occlusive thmmbus in the mechanically 
narrowed coronary artery of anesthetized dogs. High doses 
of aspirin (20 m&g body weight) stabilized coronary blood 
flow, prolonged time to thrombus formation, decreased the 
frequency of thrombotic occlusion, reduced intracoronary 
platelet thrombus mass and diminished adherence of plate- 
lets on the intimal surface of the injured coronary artery. In 
contrast, low doses of aspirin (4.6 &kg) given intcave- 
nously or orally (18 h before the experiment) did not exert 
any of these protective effects. 
Da anlmrd mud&s r&et arterial disease in hun~aus? This 
study prompts reexamination of the optimal dose of aspirin 
for prevention of myocardial or cerebral [or other regional) 
ischemic events. It also emphasizes the paradox of the 
clinical efficacy of oral low dose aspirin in humans with 
atherosclerosis and thrombosis but its inefficacy in expcri- 
mental animal models of thrombosis. It is likely that the 
mechanisms of thrombosis in animal models and humans are 
fundamentally different. Atherosclerosis in humans evolves 
over decades and involves sl~i; and continuous perturba- 
tions not only in platelet function and the coagulation 
cascade but also in vascular cell biology and the immune 
system (Z-5). An infectious etiology in the genesis of athero- 
sclerosis has also been proposed (61. The basis of acute 
thrombus formation resulting in acute myocardial ischemia, 
however, remains unclear, but may involve dynamic 
changes in flow velocity and shear stress resulting in rupture 
of atherosclerotic plaque and facilitation of platelet deposi- 
tion. In comrast, thrombus formation in animal models 
generally involves anesthesia, placement of mechanical oc- 
cluden and delivery of intravascular electrical current or 
nists in different species. This latterpaintis relevant because 
the rationale for the use of aspirin in preventing arterial 
thrombosis rests on ifs ability to inhibit platelet activity. 
Platelet activitr arid v . It is assumed IhaI 
thrombus formation in arteries is inhibited by aspirin as 
platelet aggregation is diminished. Platelet “hyperactivity” 
has indeed been identifipd in paIients with diabetes mellitus, 
hypertension. history of smoking or hypcriipidemia, con&- 
lions that arc considered risk factors io the genesis of 
ischemic heart disease (9). platelet activation is associated 
with release of serotonin. 1hromboxan.e A, ad cndoperox- 
ides. which are potent proathemsclemtic. vasocoostrictor 
and ~l~~ei~~~s:~rnuiatory factors (29.10). Release of beta- 
thromboglobulin from alpha granules of activated platelets 
promotes intravascular coagulation by inhibiting prostacy- 
clin production (41). Aatelet factor 4, another product re- 
leased from alpha granules, promotes thrombosis by neutral- 
izing hcparan sulfate in the endothelium. Rclcasc of growth 
factors from platelets induces vascular smooth muscle hy- 
pertrophy ?nd hyperplasia, which are domiuaot features of 
arteriosclerosis (2.9). Thus the ;ationale for the use of aspirin 
to suppress platelet activity sad preven: th:ombos formation 
in atheroscler& arteries is theoretically sounrl. 
Aspirin has been trier! in 
severai thousands of patients with a varimy of vascular 
diseases in an attempt to reduce ntotidity and mortality. 
Most. but not all. clinical trials have shown benefit ofaspirin 
in reducing morbidity and mortality in patients with prior 
myocardial infarction. A meta-analysis (12) of 25 trials of 
aspirin in ~18.ONlpatients showed a significant reduction in 
cardiovascalar events including rcinfarction, strokes ami 
death. All do;es of aspirin, whether low or high, were found 
to be equally beneficial. However, the higher doses resulted 
in more side effects. 
In addition to the studies in patients with myocardial 
infarction, trials in patients with stable or unstable angina 
pcctoris and others undergoing coronary Ihrombolysis or 
coronary artery bypass graft& have shown aspirin to be 
very beneficial in reducing the incidence of evolution of 
myocardial infarction, mortality rate and frequency of graft 
occlusion. We (13) have recently summarized the results of 
these trials and concluded that aspirin in a daily dose of as 
low as 80 mg taken orally is statistically as effective as much 
higher doses. 
A more recent meta-analysis (unpublished data) of 207 
random trials involvine I15.701 oatients with a varietv of 
disease states shows that aspirin therapy significantly~de- 
creases the occurrence of myocardial infarction, stroke, 
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pulmonary embolism, arieriai graft occlusion and death. 
This m&-analysis also showed that aspirin in doses of 
~325 mglday was as effective as high doses. Notably, 
primary prevention trials have demonstrated that aspirin can 
reduce cardiovascular events even when given in doses as 
low as 325 mg on alternate davs (14.19. 
Non-pl&&Cmediated e&s ‘k ‘aspirin. Despite these 
timiSiiii_ beneficial effects ofaspirin in patients with vascular 
disease, aspinn in the usual dose of 325 mg (or 4 to 5 m&g) 
is not effective (I), or only partially effective (t6), in animal 
models. In addition, other nonsteroid anti-iuflammatory 
drugs that, like aspirin, inhibit the enzyme cyclooxygenase 
in platelets and thus inhibit thromboxane A, formation do 
not decrease the incidence of cardiovascular events in 
humans or the frequency of thrombosis in animal models. 
This finding suggests that the beneficial effect of aspirin may 
not be related solely to tbc inhibition of thromboxane A, 
synthesis and plateid aggregation. It is noteworthy thai 
selective thromboxaue At synthetase or receptor antagonists 
have not shown salutary effects in patients with vasculac 
disease (18). funher calling into queptian tbe importance of 
aspirin’s inhibitory effect on cyclooxygenase enzyme acfiv- 
ity in its beneficial effects in patients with coronary disease. 
In this context, non-platelet-mediated effects of aspirin 
may explain the clinical observations as well as lack of 
benefit (I) or minimal benefit (17) of aspirin in animal 
models. A number of studies implicate long-standing pertur- 
bations in the immune svstem (4.5) and Ieukocvte (19) and . . ., 
vascularbiology (3) in the genesisof atherosclerosis. Aspirin 
inhibits prostaglandin and interleukind synthesis in leuko- 
cytes (20). It also prevents “leukocyte rolling” (moving 
dong the blood vessel wall at low velocity) (21) aud ma& 
rophage-induced activation of fibroblastic cells (22). Aspirin 
also decreases nicotine-induced endothelial activation (23) 
as weII as the activity of eodothelial nitric oxide inhibitors 
(24). Other studies (25) have shown that aspirin reduces 
hypoxia-induced coronary artery vasoconstrictian, the pro- 
contractile effects of activated neutrophils on the pulmonary 
artcry (26) and vascular growth after de-endothelialization 
(27). A study by Yousefi et al. (28) indicates that aspirin 
increases interleukint and interferon production in human 
lymphocytes. It also decreases catecholamine-induced vase- 
constriction and lipolysis (29). Almost 20 years ago, 
Moschos et al. (30) showed that aspirin reduces arrhythmias 
in platelet-depleted animals by platelet-independent mecha- 
nisms. 
Each of these effects of aspirin on cells other than 
platelets may decrase the risk of progression of vascular 
disease as well as acute thrombus formation in atheroscle- 
rotic arteries. The abnormalities in vascular biology clearly 
identified in humans are not present in animals with normal 
blood vessels that are subjected to experimental intravascu- 
lar thrombosis. The cellular abnormalities seen in long- 
standing vascular disease in humans are also not present in 
animal models of acute arterial thrombosis. This may explain 
the failure of short-term aspirin therapy in conventional 
doses to prevent thrombus formation in experimental ani- 
mals. 
Clinical implications. Aspirin has proved its place in the 
management of patients with vascular disease. Despite its 
widespread use, the precise mechanism of action and the 
optimal dosage of aspirin remain unclear. Nevertheless, it is 
likely that aspirin will continue to be used by physicians and 
their patients and that another agent as useful. safe and 
inexpensive is unlikely to displace it from its special position 
in the foreseeable future. 
We thank Emily Ohland for secretarial assistance in the preparation of this 
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